Cell Therapeutics Opens Phase 3 Trial Enrollment for Pacritinib

Biotech firm Cell Therapeutics (NASDAQ: CTIC  ) announced Wednesday that it has begun enrollment of patients in a phase 3 trial of its myelofibrosis drug pacritinib.

The PERSIST-1 trial for pacritinib is expected by the company to enroll 270 patients. Myelofibrosis patients in pacritinib's phase 2 trial showed clinical benefits and tolerated the drug well, according to Cell Therapeutics, making the PERSIST-1 trial a key step up for the drug's progress.

Myelofibrosis is estimated to afflict around 30,000 individuals in the United States. The disease, a chronic bone marrow disorder, can cause an enlarged spleen, anemia, and extreme fatigue, among other symptoms.

Company Chief Medical Officer Dr. Steven E. Benner talked about the trial in a company press release, saying, "Data from earlier studies of pacritinib showed a clinically meaningful improvement in symptoms without suppression of platelets or red blood cells. We believe that pacritinib has the potential to offer an effective and well-tolerated treatment option for myelofibrosis patients, and are pleased to be initiating the Phase 3 PERSIST-1 clinical trial." 

link


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2187598, ~/Articles/ArticleHandler.aspx, 9/18/2014 8:08:54 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement